Lymphoma
Conditions
Keywords
Lymphoma, positron emission tomography, stem cell transplantation, therapeutic impact
Brief summary
This randomised study aimed at evaluating the medical and economical impact of positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) in the therapeutic prescription in patients with Hodgkin's lymphoma or with large B and P cell non-Hodgkin's lymphoma. The median progression free survival, the costs and the quality of life are compared between two groups : Group 1: the results of conventional staging and of the PET are known before stem cell transplantation. Group 2: only the results of conventional staging before stem cell transplantation are known before stem cell transplantation.
Interventions
PROCEDUREpositron emission tomography
Sponsors
Hospices Civils de Lyon
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Age over 18, with Hodgkin's lymphoma or with large B and P cell non-Hodgkin's lymphoma, or after a first-line chemotherapy with at least a residual mass or after induction chemotherapy or at progression. Stem cell transplantation would be programmed. Patients were required to give their written informed consent.
Exclusion criteria
Progressive cancer or diagnosed less than 5 years, except cancer in situ of the cervix and basocell skin carcinoma, kidney insufficiency or diabetes. Patients would not be pregnant or lactating
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The impact of positron emission tomography (PET) using fluorine-18-floro-deoxyglucose (FDG) in the therapeutic prescription in patients with Hodgkin's lymphoma or with large B and P cell non-Hodgkin's lymphoma. | — |
Secondary
| Measure | Time frame |
|---|---|
| The positive and negative likelihood- ratios, the positive and negative predictive values | — |
| The costs | — |
| The one-year survival rates | — |
| The quality of life of the patients | — |
| Median progression free survival | — |
Countries
France
Outcome results
None listed